Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Gan To Kagaku Ryoho ; 51(5): 567-570, 2024 May.
Article in Japanese | MEDLINE | ID: mdl-38881070

ABSTRACT

A 74-year-old man underwent laparoscopic-assisted high anterior resection with D3 lymph node dissection for rectal cancer, which was simultaneously accompanied by multiple liver metastases. The patient received mFOLFOX6 therapy for liver metastases 1 month after the surgery. Anorexia, nausea, and vomiting appeared on the second day of treatment. On the third day of treatment, impaired consciousness(JCS Ⅱ-20)and flapping tremors appeared. Blood tests revealed hyperammonemia, and the patient was diagnosed with impaired consciousness due to hyperammonemia, which was inferred to be caused by 5-fluorouracil(5-FU). Intravenous infusion and branched-chain amino acids were administered, and the patient recovered. The underlying disease of renal dysfunction, constipation, and dehydration due to chemotherapy might have induced the hyperammonemia. It is important to note that hyperammonemia can lead to a disturbance of consciousness during chemotherapy including 5-FU.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Consciousness Disorders , Fluorouracil , Hyperammonemia , Leucovorin , Liver Neoplasms , Organoplatinum Compounds , Rectal Neoplasms , Humans , Hyperammonemia/chemically induced , Male , Fluorouracil/adverse effects , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Aged , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leucovorin/adverse effects , Leucovorin/therapeutic use , Leucovorin/administration & dosage , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/administration & dosage , Liver Neoplasms/secondary , Liver Neoplasms/drug therapy , Consciousness Disorders/etiology , Consciousness Disorders/chemically induced
2.
Biomed Chromatogr ; 30(3): 384-9, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26174062

ABSTRACT

Elution profiles of kynurenic acid (KYNA) and 7-chlorokynurenic acid (Cl-KYNA) were examined by high-performance liquid chromatography (HPLC) using a triazole-bonded stationary phase column (Cosmosil® HILIC) under isocratic elution of a mobile phase consisting of CH3 CN-aqueous 10 mm ammonium formate between pH 3.0 and 6.0. The capacity factors of KYNA and Cl-KYNA varied with both the CH3 CN content and the pH of the mobile phase. The elution order of KYNA and Cl-KYNA was reversed between the CH3 CN- and H2 O-rich mobile phases, suggesting that hydrophilic interactions and anion-exchange interactions caused retention of KYNA and Cl-KYNA in the CH3 CN- and H2 O-rich mobile phases, respectively. The present HPLC method using a triazole-bonded column and fluorescence detection (excitation 250 nm, emission 398 nm) was applied to monitor in vitro production of KYNA from d-kynurenine (d-KYN) by d-amino acid oxidase (DAO) using Cl-KYNA as an internal standard. A single KYNA peak was clearly observed after enzymatic reaction of d-KYN with DAO. Production of KYNA from d-KYN was suppressed by the addition of commercial DAO inhibitors. The present HPLC method can be used to evaluate DAO activity and DAO inhibitory effects in candidate drugs for the treatment of schizophrenia.


Subject(s)
Chromatography, High Pressure Liquid/methods , D-Amino-Acid Oxidase/metabolism , Kynurenic Acid/analysis , Triazoles/chemistry , Hydrophobic and Hydrophilic Interactions , Kynurenic Acid/analogs & derivatives , Kynurenic Acid/chemistry , Kynurenic Acid/metabolism , Kynurenine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...